Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID‐19 Trial of Nirmatrelvir
Ravi Shankar Prasad Singh, Sima S. Toussi, Frances Hackman, et al.
Clinical Pharmacology & Therapeutics (2022) Vol. 112, Iss. 1, pp. 101-111
Open Access | Times Cited: 137

Showing 1-25 of 137 citing articles:

A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies
Monika Kumari, Ruei‐Min Lu, Mu‐Chun Li, et al.
Journal of Biomedical Science (2022) Vol. 29, Iss. 1
Open Access | Times Cited: 111
Paxlovid: Mechanism of Action, Synthesis, and In Silico Study
Mahrokh Marzi, Mohammad Kazem Vakil, Maryam Bahmanyar, et al.
BioMed Research International (2022) Vol. 2022, pp. 1-16
Open Access | Times Cited: 103
Accelerating antiviral drug discovery: lessons from COVID-19
Annette von Delft, Matthew D. Hall, Ann D. Kwong, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 7, pp. 585-603
Open Access | Times Cited: 94
Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?
Seyed Mohammad Reza Hashemian, Amirhossein Sheida, Mohammad Taghizadieh, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 162, pp. 114367-114367
Open Access | Times Cited: 90
Small molecules in the treatment of COVID-19
Sibei Lei, Xiaohua Chen, Jieping Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 78
An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines
V. Edwin Hillary, Stanislaus Antony Ceasar
Heliyon (2023) Vol. 9, Iss. 3, pp. e13952-e13952
Open Access | Times Cited: 76
A Comprehensive Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Nirmatrelvir/Ritonavir
Jacqueline G. Gerhart, Donna S. Cox, Ravi Shankar Prasad Singh, et al.
Clinical Pharmacokinetics (2024) Vol. 63, Iss. 1, pp. 27-42
Open Access | Times Cited: 20
A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19
Charlotte Allerton, Joel T. Arcari, Lisa Aschenbrenner, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 16, pp. 13550-13571
Open Access | Times Cited: 20
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19
Stefanie Reis, Maria‐Inti Metzendorf, Rebecca Kuehn, et al.
Cochrane library (2022) Vol. 2022, Iss. 9
Open Access | Times Cited: 53
SARS-CoV-2 Mpro Inhibitors: Achieved Diversity, Developing Resistance and Future Strategies
Conrad Fischer, Jenson R. Feys
Future Pharmacology (2023) Vol. 3, Iss. 1, pp. 80-107
Open Access | Times Cited: 24
Is antiviral treatment at the acute phase of COVID-19 effective for decreasing the risk of long-COVID? A systematic review
César Fernández‐de‐las‐Peñas, Juan Torres‐Macho, Jesus Alfonso Catahay, et al.
Infection (2023) Vol. 52, Iss. 1, pp. 43-58
Closed Access | Times Cited: 23
Comparing molnupiravir and nirmatrelvir/ritonavir efficacy and the effects on SARS-CoV-2 transmission in animal models
Robert M. Cox, Carolin M. Lieber, Josef D. Wolf, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 22
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19
Stefanie Reis, Maria‐Inti Metzendorf, Rebecca Kuehn, et al.
Cochrane library (2023) Vol. 2023, Iss. 11
Open Access | Times Cited: 22
An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations
Michael Westberg, Yichi Su, Xinzhi Zou, et al.
Science Translational Medicine (2024) Vol. 16, Iss. 738
Open Access | Times Cited: 12
COVID-19 therapeutics
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 10
A unifying model to explain frequent SARS-CoV-2 rebound after nirmatrelvir treatment and limited prophylactic efficacy
Shadisadat Esmaeili, Katherine Owens, Jessica Wagoner, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 7
Simultaneous determination of nirmatrelvir and ritonavir in human plasma using LC–MS/MS and its pharmacokinetic application in healthy Chinese volunteers
Chenxi Liu, Miqun Zhu, Liyun Cao, et al.
Biomedical Chromatography (2022) Vol. 36, Iss. 11
Closed Access | Times Cited: 32
Association of Nirmatrelvir/Ritonavir Treatment on Upper Respiratory Severe Acute Respiratory Syndrome Coronavirus 2 Reverse Transcription-Polymerase Chain Reaction (SARS-Cov-2 RT-PCR) Negative Conversion Rates Among High-Risk Patients With Coronavirus Disease 2019 (COVID-19)
Hongyan Li, Menghan Gao, Hailong You, et al.
Clinical Infectious Diseases (2022) Vol. 76, Iss. 3, pp. e148-e154
Open Access | Times Cited: 27
Early Clinical Development of Lufotrelvir as a Potential Therapy for COVID-19
Christophe Allais, David J. Bernhardson, Adam R. Brown, et al.
Organic Process Research & Development (2023) Vol. 27, Iss. 12, pp. 2223-2239
Closed Access | Times Cited: 19
Nirmatrelvir exerts distinct antiviral potency against different human coronaviruses
Jiajing Li, Yining Wang, Kundan Solanki, et al.
Antiviral Research (2023) Vol. 211, pp. 105555-105555
Open Access | Times Cited: 18
A comprehensive review on the global efforts on vaccines and repurposed drugs for combating COVID-19
Narva Deshwar Kushwaha, Jivanka Mohan, Babita Kushwaha, et al.
European Journal of Medicinal Chemistry (2023) Vol. 260, pp. 115719-115719
Open Access | Times Cited: 17
Inhibitors of SARS-CoV-2 Main Protease (Mpro) as Anti-Coronavirus Agents
Agnieszka Zagórska, Anna Czopek, Monika Fryc, et al.
Biomolecules (2024) Vol. 14, Iss. 7, pp. 797-797
Open Access | Times Cited: 6
Application of model-informed drug development (MIDD) for dose selection in regulatory submissions for drug approval in Japan
T. Sasaki, Takayuki Katsube, Seiichi Hayato, et al.
Journal of Pharmacokinetics and Pharmacodynamics (2025) Vol. 52, Iss. 1
Closed Access
Real-world Plasma Exposure of Nirmatrelvir/Ritonavir in Chinese Hospitalized Patients With COVID-19: A Multicenter Retrospective Study
Zhiyuan Ma, Mengru Bai, Shuying Shen, et al.
Therapeutic Drug Monitoring (2025)
Open Access
Single- and multiple-dose pharmacokinetics and safety of the SARS-CoV-2 3CL protease inhibitor RAY1216: a phase 1 study in healthy participants
Yue Hu, Haijun Li, Kun Wang, et al.
Antimicrobial Agents and Chemotherapy (2025) Vol. 69, Iss. 3
Open Access
Page 1 - Next Page

Scroll to top